|
RNAZ Transcode Therapeutics Inc 1829635 |
| Income Statement |
|
Net Income
|
2026-03-31
|
$-17,785,071.00 |
| Balance Sheet |
|
Current Assets
|
$16,748,994.00 |
|
Assets
|
$157,164,882.00 |
|
Current Liabilities
|
$5,378,570.00 |
|
Liabilities
|
$12,643,694.00 |
|
Equity
|
$1,251,427.00 |
|
Shares Out
|
916968.00 |
| Cash Flow Statement |
|
Operating Cash Flow
|
$-4,978,067.00 |
|
Investing Cash Flow
|
$-4,436.00 |
| Market Analysis |
Market Cap
|
$4,814,082.00 |
|
Price
|
$4.56 |
|
BVPS
|
1.36 |
|
PB
|
3.86 |
|
EPS
|
-21.28 |
|
FCF
|
$-4,984,727.00 |
|
| Dividends |
|
Dividend Data Last Updated
|
2026-08-01 09:31:46 |
|
|
| Earnings |
|
Earnings Last Updated
|
2026-08-03 10:01:47 |
|
|
|
Find a discrepancy? The most accurate way to find company fundamental data is to view RNAZ documents filed with the SEC.
RNAZ Filings
Clear
